CA3169665C - Composition pharmaceutique comprenant de la dapagliflozine - Google Patents

Composition pharmaceutique comprenant de la dapagliflozine

Info

Publication number
CA3169665C
CA3169665C CA3169665A CA3169665A CA3169665C CA 3169665 C CA3169665 C CA 3169665C CA 3169665 A CA3169665 A CA 3169665A CA 3169665 A CA3169665 A CA 3169665A CA 3169665 C CA3169665 C CA 3169665C
Authority
CA
Canada
Prior art keywords
dapagliflozin
granulate
tablet
filler
comprised
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3169665A
Other languages
English (en)
Other versions
CA3169665A1 (fr
Inventor
Mateusz Kaczmarek
Szymon Przerada
Julia Hrakovsky
Jakub Dzik
Original Assignee
Zaklady Farmaceutyczne Polpharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zaklady Farmaceutyczne Polpharma SA filed Critical Zaklady Farmaceutyczne Polpharma SA
Priority claimed from PCT/EP2021/053880 external-priority patent/WO2021165316A1/fr
Publication of CA3169665A1 publication Critical patent/CA3169665A1/fr
Application granted granted Critical
Publication of CA3169665C publication Critical patent/CA3169665C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne une composition de granulés de dapagliflozine, qui est appropriée pour la préparation de capsules ou de comprimés. L'invention concerne également une forme posologique pharmaceutique pour l'administration orale qui comprend de tels granulés. L'invention concerne également un procédé de préparation du granulé de dapagliflozine et l'utilisation des formes posologiques le contenant pour le traitement du diabète sucré.
CA3169665A 2020-02-21 2021-02-17 Composition pharmaceutique comprenant de la dapagliflozine Active CA3169665C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20460013 2020-02-21
EPEP20460013 2020-02-21
PCT/EP2021/053880 WO2021165316A1 (fr) 2020-02-21 2021-02-17 Composition pharmaceutique comprenant de la dapagliflozine

Publications (2)

Publication Number Publication Date
CA3169665A1 CA3169665A1 (fr) 2021-08-26
CA3169665C true CA3169665C (fr) 2025-07-29

Family

ID=

Similar Documents

Publication Publication Date Title
JP6574417B2 (ja) 非晶質ダパグリフロジンを含有する製剤
AU2019280026B2 (en) Galenic formulations of organic compounds
CA2467490C (fr) Compositions pharmaceutiques de 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
AU2010205684B2 (en) Active coating of pharmaceutical dosage forms
WO2021165316A1 (fr) Composition pharmaceutique comprenant de la dapagliflozine
CA2740146A1 (fr) Formes posologiques a liberation immediate d'oxybate de sodium
EP4114365A1 (fr) Composition pharmaceutique comprenant un inhibiteur du sglt2
US20150283248A1 (en) Pharmaceutical compositions of Linagliptin and process for preparation thereof
MX2014007700A (es) Nueva combinacion.
HUP9902878A2 (hu) Trimebutin-maleát filmtabletta
CN101516356A (zh) 琥珀酸美托洛尔缓释片及其制备方法
KR102369679B1 (ko) 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제
JP7212484B2 (ja) 腸溶性被覆顆粒の耐酸性が改善された圧縮成形製剤の製造方法
AU2002314306C1 (en) Pharmaceutical composition containing stool softener such as polaxamer and enteric coated particles of bisacodyl
EP1216032B1 (fr) Formulations orales a liberation controlee
WO2009027786A2 (fr) Formes posologiques matricielles de varénicline
CN105407875A (zh) 包含异烟肼颗粒和利福喷汀颗粒的呈包衣片剂形式的抗结核病的稳定的药物组合物及其制备方法
CA3169665C (fr) Composition pharmaceutique comprenant de la dapagliflozine
US20070104789A1 (en) Gastro-resistant and ethanol-resistant controlled-release formulations comprising hydromorphone
EP3796908B1 (fr) Formulations de propivérine à libération contrôlée
EA049514B1 (ru) Фармацевтическая композиция, содержащая дапаглифлозин
EP4279075B1 (fr) Composition pharmaceutique contenant de l'elagolix
JP2021518424A (ja) 様々な用量のレナリドミドの経口用錠剤組成物
EP4580636A1 (fr) Thérapie anticoagulante avec un régime posologique amélioré